The Lonza Board of Directors announced the nomination of Stephen Fry as an Independent Member of the Board, pending his election at the company's Annual General Meeting in May 2026. If elected, Fry will also join the People and Governance Committee and the Audit and Compliance Committee.
Fry brings over three decades of experience from Eli Lilly and Company, where he served as Executive Vice President and Chief Human Resources Officer for 12 years. In that role, he led large-scale organizational transformation, shaped high-performance cultures, and guided the company through significant change. His global leadership perspective and deep pharmaceutical industry expertise are expected to complement the existing board capabilities.
Jean-Marc Huet, Chairman of the Lonza Board, commented, 'Stephen brings extensive international experience, combined with a strong track record in organizational governance, succession planning and people strategy development, all of which form a valuable complementary fit with the capabilities of our other Board members. Stephen will play an important role in helping develop and embed our performance culture.'
This nomination comes as Lonza, the world's largest contract development and manufacturing organization (CDMO), continues to focus on attracting and retaining top talent to support its high-performing teams. The company, which generated sales of CHF 6.5 billion in 2025, serves the healthcare industry by working with pharma and biotech companies to bring therapies to patients worldwide.
Fry also serves as a Member of the Board of Trustees at the University of Indianapolis. His nomination underscores Lonza's commitment to strengthening its governance and people strategy as it navigates the evolving healthcare landscape.
For more information about Lonza, visit www.lonza.com. The original release can be accessed at www.newmediawire.com.
